Weekly Analysts’ Ratings Changes for Kyverna Therapeutics (KYTX)

Several analysts have recently updated their ratings and price targets for Kyverna Therapeutics (NASDAQ: KYTX):

• 5/30/2026 – Kyverna Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 5/16/2026 – Kyverna Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 5/15/2026 – Kyverna Therapeutics had its price target raised by HC Wainwright from $20.00 to $25.00. They now have a “buy” rating on the stock.
• 5/13/2026 – Kyverna Therapeutics had its price target lowered by JPMorgan Chase & Co. from $30.00 to $29.00. They now have an “overweight” rating on the stock.
• 4/23/2026 – Kyverna Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $20.00 price target on the stock.

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.